V. Hugh Perry

V. Hugh Perry

Auto-generated profile, based on publicly available information

V. Hugh Perry

University of Southampton

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2007 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
VPV. Hugh Perry
V. Hugh Perry
CCColm Cunningham
Colm Cunningham
CHClive Holmes
Clive Holmes


1 February 2003 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
VPV. Hugh Perry
V. Hugh Perry
TNTracey A. Newman
Tracey A. Newman
CCColm Cunningham
Colm Cunningham

20 July 2010 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
VPV. Hugh Perry
V. Hugh Perry

1 June 2002 in Current Opinion in Neurology
Verified
Journal Article
Closed access
HPHugh V. Perry
Hugh V. Perry
CCColm Cunningham
Colm Cunningham
DBDelphine Boche
Delphine Boche
The inflammatory response in prion diseases is dominated by microglial activation. Contrary to their profile in vitro none of the pro-inflammatory cytokines interleukin-1beta, interleukin-6, or tumour necrosis factor-alpha are significantly upregulated in the ME7 model of prion disease. However, two major inflammatory mediators are elevated: transforming growth factor-beta1 and prostaglandin E2. This cytokine profile is the same as that reported for macrophages during phagocytosis of apoptotic cells and indeed transforming growth factor-beta1 and prostaglandin E2 are responsible for the downregulated phenotype of these macrophages. Transforming growth factor-beta1 may also have roles in extracellular matrix deposition and in amyloidogenesis and may play a direct role in disease pathogenesis. There is also now evidence to suggest that a peripheral infection, and its consequent systemic cytokine expression, may drive central nervous system cytokine expression and perhaps exacerbate disease.

27 June 2012 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
UPUrsula Püntener
Ursula Püntener
SBSteven G Booth
Steven G Booth
VPV Hugh Perry
V Hugh Perry
JTJessica L Teeling
Jessica L Teeling
Background: Systemic infection leads to generation of inflammatory mediators that result in metabolic and behavioural changes. Repeated or chronic systemic inflammation leads to a state of innate immune tolerance: a protective mechanism against overactivity of the immune system. In this study, we investigated the immune adaptation of microglia and brain vascular endothelial cells in response to systemic inflammation or bacterial infection.Methods: Mice were given repeated doses of lipopolysaccharide (LPS) or a single injection of liveSalmonella typhimurium. Inflammatory cytokines were measured in serum, spleen and brain, and microglial phenotype studied by immunohistochemistry. To assess priming of the innate immune response in the brain, mice were infected withSalmonella typhimuriumand subsequently challenged with a focal unilateral intracerebral injection of LPS.Results: Repeated systemic LPS challenges resulted in increased brain IL-1β, TNF-α and IL-12 levels, despite attenuated systemic cytokine production. Each LPS challenge induced significant changes in burrowing behaviour. In contrast, brain IL-1β and IL-12 levels inSalmonella typhimurium-infected mice increased over three weeks, with high interferon-γ levels in the circulation. Behavioural changes were only observed during the acute phase of the infection. Microglia and cerebral vasculature display an activated phenotype, and focal intracerebral injection of LPS four weeks after infection results in an exaggerated local inflammatory response when compared to non-infected mice.Conclusions: These studies reveal that the innate immune cells in the brain do not become tolerant to systemic infection, but are primed instead. This may lead to prolonged and damaging cytokine production that may have a profound effect on the onset and/or progression of pre-existing neurodegenerative disease.